BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23804564)

  • 1. Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.
    Wang J; Li D; Bambara RA; Dykes C
    J Gen Virol; 2013 Oct; 94(Pt 10):2297-2308. PubMed ID: 23804564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.
    Wang J; Li D; Bambara RA; Yang H; Dykes C
    J Gen Virol; 2013 Jul; 94(Pt 7):1597-1607. PubMed ID: 23535575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.
    Wang J; Liang H; Bacheler L; Wu H; Deriziotis K; Demeter LM; Dykes C
    Virology; 2010 Jul; 402(2):228-37. PubMed ID: 20399480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.
    Wang J; Bambara RA; Demeter LM; Dykes C
    J Virol; 2010 Sep; 84(18):9377-89. PubMed ID: 20592075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
    Wang J; Zhang G; Bambara RA; Li D; Liang H; Wu H; Smith HM; Lowe NR; Demeter LM; Dykes C
    J Virol; 2011 Oct; 85(20):10861-73. PubMed ID: 21835788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency.
    Wang J; Dykes C; Domaoal RA; Koval CE; Bambara RA; Demeter LM
    Virology; 2006 May; 348(2):462-74. PubMed ID: 16504235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.
    Archer RH; Dykes C; Gerondelis P; Lloyd A; Fay P; Reichman RC; Bambara RA; Demeter LM
    J Virol; 2000 Sep; 74(18):8390-401. PubMed ID: 10954539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.
    Gerondelis P; Archer RH; Palaniappan C; Reichman RC; Fay PJ; Bambara RA; Demeter LM
    J Virol; 1999 Jul; 73(7):5803-13. PubMed ID: 10364332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
    Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
    Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
    Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase.
    Julias JG; Ferris AL; Boyer PL; Hughes SH
    J Virol; 2001 Jul; 75(14):6537-46. PubMed ID: 11413321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct drug resistance profile of HIV-1 subtype A strain circulating in Georgia.
    Dvali N; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Georgian Med News; 2015 Mar; (240):19-24. PubMed ID: 25879553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
    Trivedi V; Von Lindern J; Montes-Walters M; Rojo DR; Shell EJ; Parkin N; O'Brien WA; Ferguson MR
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1291-300. PubMed ID: 18844463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and antiviral evaluation of novel heteroarylcarbothioamide derivatives as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and RDDP functions.
    Corona A; Onnis V; Deplano A; Bianco G; Demurtas M; Distinto S; Cheng YC; Alcaro S; Esposito F; Tramontano E
    Pathog Dis; 2017 Aug; 75(6):. PubMed ID: 28859311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
    Pelemans H; Esnouf RM; Jonckheere H; De Clercq E; Balzarini J
    J Biol Chem; 1998 Dec; 273(51):34234-9. PubMed ID: 9852086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
    Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
    Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone.
    Borkow G; Fletcher RS; Barnard J; Arion D; Motakis D; Dmitrienko GI; Parniak MA
    Biochemistry; 1997 Mar; 36(11):3179-85. PubMed ID: 9115994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones.
    Arion D; Sluis-Cremer N; Min KL; Abram ME; Fletcher RS; Parniak MA
    J Biol Chem; 2002 Jan; 277(2):1370-4. PubMed ID: 11684697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations at amino acid positions 63, 189, and 396 of human immunodeficiency virus type 1 reverse transcriptase (RT) partially restore the DNA polymerase activity of a Trp229Tyr mutant RT.
    Pelemans H; Esnouf R; Min KL; Parniak M; De Clercq E; Balzarini J
    Virology; 2001 Aug; 287(1):143-50. PubMed ID: 11504549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutagenesis of cysteine 280 of the reverse transcriptase of human immunodeficiency virus type-1: the effects on the ribonuclease H activity.
    Sevilya Z; Loya S; Duvshani A; Adir N; Hizi A
    J Mol Biol; 2003 Mar; 327(1):19-30. PubMed ID: 12614605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.